Private equity health care specialist, ArchiMed has acquired ActiGraph, a developer of wearable, remote monitoring technology for academic studies and drug trials. ActiGraph provides mobility and sleep tracking hardware, software, and analysis solutions for research-grade monitoring systems. ActiGraph’s monitoring devices resemble watches and can be worn on the wrist, waist ankle, or thigh.
In the all-equity deal, ArchiMed is acquiring 75% of ActiGraph from historic shareholders, including management. Management will retain 10% of the company with other historic shareholders keeping 15%. Financial terms were not disclosed.
ArchiMed is an independent investment firm specialized in the health care industries. It is a strategic and financial partner to European and North American companies operating in the biopharma, medtech, diagnostics, life sciences, health care IT, consumer health, public safety, and care services sectors.
Based in Pensacola, Florida and founded in 2004, ActiGraph was originally focused on providing technology for a wide range of academic studies involving the monitoring of sleep and movement. Over the last half decade, enabled by the steady refinement of its technology, ActiGraph has aggressively branched into the fast-growing field of remote activity and sleep monitoring for medical research and drug trials.
This was reported by ArchiMed on May 18, 2020.